Fig. 6.
IgE immunoblots revealed with a pooled serum obtained from CMA patients. Lane 1: CM immunoblotting under reducing conditions, lane 2: soybean immunoblotting (under non reducing conditions), lane 3: S30 immunoblotting under nonreducing conditions, lane 4: S30 immunoblotting under reducing conditions.